Ileus News and Research RSS Feed - Ileus News and Research

Ileus or gastrointestinal atony is a disruption of the normal propulsive gastrointestinal motor activity due to non-mechanical causes.
ESCMID releases new guidelines on best practices to detect C. difficile infections

ESCMID releases new guidelines on best practices to detect C. difficile infections

The European Society of Clinical Microbiology and Infectious Diseases has just released new guidelines on best practice methods to diagnose Clostridium difficile infection (CDI). [More]
Study finds that ACS NSQIP Surgical Risk Calculator has excellent calibration

Study finds that ACS NSQIP Surgical Risk Calculator has excellent calibration

The American College of Surgeons National Surgical Quality Improvement Program Surgical Risk Calculator accurately estimates the chance of a patient experiencing postoperative complications, and its performance can improve with recalibration of the tool according to research findings appearing online in the Journal of the American College of Surgeons in advance of print publication. [More]
Human-gut-on-a-chip model offers hope for patients suffering from IBD

Human-gut-on-a-chip model offers hope for patients suffering from IBD

It's estimated that as many as 1,000,000 Americans suffer from inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn's disease, which cause mild to severe symptoms that at best can be managed and at worst can lead to life-threatening complications. [More]
Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States. [More]
Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics announces availability of codeine-based cough and cold syrup in the U.S.

Vernalis Therapeutics Inc., a subsidiary of Vernalis plc, today announced that Tuzistra XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral suspension, CIII (DEA Schedule III) is now available to adult patients and physicians in the United States. [More]
Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII. [More]
Egalet announces net revenues of $1.9 million for 2014

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014. [More]
Readmissions after surgery associated with new postdischarge complications, shows study

Readmissions after surgery associated with new postdischarge complications, shows study

In a study that included readmission information from nearly 350 hospitals, readmissions the first 30 days after surgery were associated with new postdischarge complications related to the surgical procedure and not a worsening of any medical conditions the patient already had while hospitalized for surgery, according to a study in the February 3 issue of JAMA. [More]
Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Colonoscopy is an important and widely used screening tool for colorectal cancer, but for many patients the bowel-preparation process is more uncomfortable than the procedure itself. To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc. will introduce a new cranberry flavor option of PREPOPIK in January 2015. [More]
Fecal microbiota transplantation officially recommended for effective treatment of C. difficile infection

Fecal microbiota transplantation officially recommended for effective treatment of C. difficile infection

The transplantation of faecal microbiota from a healthy donor has been shown in recent clinical studies to be a safe and highly effective treatment for recurrent Clostridium difficile (C. difficile) infection and is now recommended in European treatment guidelines. [More]
New disposable device may help doctors to monitor post-operative ileus

New disposable device may help doctors to monitor post-operative ileus

A disposal, plastic listening device that attaches to the abdomen may help doctors definitively determine which post-operative patients should be fed and which should not, an invention that may improve outcomes, decrease healthcare costs and shorten hospital stays, according to a UCLA study. [More]
Trevena's Phase 1b data for TRV130 published in the journal Pain

Trevena's Phase 1b data for TRV130 published in the journal Pain

Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain. [More]
Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3. [More]
Report describes cardiopulmonary arrest in infant following cyclopentolate eyedrops

Report describes cardiopulmonary arrest in infant following cyclopentolate eyedrops

Eyedrops administered to infants as part of routine outpatient retinopathy of prematurity (ROP) screening can have life-threatening consequences. A case report published in the current issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) describes cardiopulmonary arrest in a 27-week-old infant following administration of three sets of cyclopentolate 0.2%/phenylephrine 1% (Cyclomydril) eyedrops. [More]
Unexpected toxicity of pazopanib/pemetrexed in NSCLC halts study

Unexpected toxicity of pazopanib/pemetrexed in NSCLC halts study

A phase II study comparing first-line combination pazopanib/pemetrexed chemotherapy with the standard cisplatin/pemetrexed treatment in non-small-cell lung cancer was terminated early owing to an increased frequency of adverse events in the experimental arm. [More]
FDA approves Prior Approval Supplement for EMBEDA Extended Release Capsules CII

FDA approves Prior Approval Supplement for EMBEDA Extended Release Capsules CII

Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved a Prior Approval Supplement for EMBEDA (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII. [More]
New recovery program for abdominal surgery patients improves recovery process

New recovery program for abdominal surgery patients improves recovery process

A new recovery program for abdominal surgery patients at University of Virginia Health System is helping patients go home sooner while making them more comfortable both before and after surgery. [More]
Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day. [More]
Cubist seeks FDA sNDA approval for ENTEREG to accelerate GI recovery

Cubist seeks FDA sNDA approval for ENTEREG to accelerate GI recovery

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval for the use of ENTEREG® (alvimopan) to accelerate GI recovery following any surgery that includes a bowel resection with primary anastomosis; expanded from the current indication in patients requiring surgery for colorectal disease. [More]
NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD). [More]
Advertisement
Advertisement